Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | EVP, CFO & Treasurer | February 03, 2026 | February 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Karyopharm Therapeutics Inc.
Report date February 03, 2026 · Filed February 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 85,105 |
Reported balance
After 2026-02-03 transaction · row 1
1 source rowRow 1 · 2026-02-03 · Sale · Disposed 1,626 · Balance 85,105 F1: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on December 19, 2024, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on December 19, 2024, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2026 Filed Feb 4, 2026 16:11 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 1,626 | $6.30 | $10,243.80 |
DisclosureSEC source: 0001193125-26-037584 · ownership.xml · nonDerivative · entry 1 Macomber Lori · CIK 0001968671 · EVP, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,105 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on December 19, 2024, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 16:29 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 32,415 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-035663 · ownership.xml · nonDerivative · entry 1 Macomber Lori · CIK 0001968671 · EVP, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,731 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 16:25 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 43,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-241461 · ownership.xml · nonDerivative · entry 1 Macomber Lori · CIK 0001968671 · EVP, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,316 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on December 31, 2026. F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 16:15 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 650,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000950170-25-012326 · ownership.xml · derivative · entry 2 Macomber Lori · CIK 0001968671 · EVP, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2035-01-30 F2 · derivative.exercise_date: This option was granted on January 31, 2025 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on January 31, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 16:15 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 160,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-012326 · ownership.xml · nonDerivative · entry 1 Macomber Lori · CIK 0001968671 · EVP, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Inducement Stock Incentive Plan, as amended (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning January 31, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.